報價延遲最少15分鐘:2026/09/01 19:04 EDT
盤後時段
|
||||
|
31.98 
|
|
|
常規時段 (已結束)
|
|
|
|
|
||||||||||||
|
|
|
|
|
31.98
|
|
|
| 價值評估 |
|
盈利(現時/預測)
-9.63/-5.11
|
|
企業價值
2.11B
|
| 資產負債 |
|
每股賬面淨值
3.79
|
| 現金流量 |
|
現金流量率
--
|
| 損益表 |
|
收益
10.00M
|
|
每股收益
--
|
|
同行比較
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
同行比較之報價最少15分鐘延遲 (夜盤時段除外)
|
業務概覽
|
|||
| Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. The Company manages its operations on a consolidated basis as a single reportable segment focused on the research, development and commercialization of transformative immunology-based therapies. |
